The latest research into stem cell therapy for NSCLC

Experts are looking at the potential of stem cell therapy in developing new therapies aimed at conditions that do not respond well to treatment, such as non-small cell lung cancer.

Non-small cell lung cancer (NSCLC) is one of the two main types of lung cancer. Evidence suggests that roughly 80–85%Trusted Source of lung cancer is NSCLC. It occurs when cells that line the lungs grow abnormally.

Lung cancer is one of the most common cancersTrusted Source worldwide and is the leading cause of cancer-related death, representing about 25%Trusted Source of cancer deaths. Most lung cancer-related deaths are due to treatment failure and the spreading of cancer cells to distant sites (metastasis).

Current research proposes that NSCLC’s resistance to treatment and fast progression is due to the presence of specific types of cancer cells, called cancer stem cells (CSCs), which have the ability of normal stem cells, allowing them to divide and proliferate.

Stem cell therapy is a field of regenerative medicine that utilizes people’s own cells to promote healing, repair damaged tissue, and help boost the immune response to fight off cancer cells and infections.

In this article, we look at whether stem cell therapy is a viable treatment for NSCLC along with other new treatment breakthroughs.

Currently, there are limited studies that prove the effectiveness of using stem cell therapy in treating NSCLC, and the majority of these are still under clinical trials. Growing evidence suggests that stem cell therapy may also have some potential to treat other lung conditions, such as chronic obstructive pulmonary disease (COPD).

While a few clinical studies suggest some promise of stem cell therapy in treating NSCLC, more research is necessary due to potential concerns regarding the effectiveness and safety of the therapy. At present, many experts do not recommend this therapy due to the potential risks, lack of proven benefits, and costs.

However, researchers continue to investigate the potential benefits. For example, a 2021 study indicates that mesenchymal stem cells may be able to inhibit NSCLC cells in a lab setting. An animal study also found that giving human-induced neural stem cells intravenously to mice was safe and reduced NSCLC tumor cells by seeking and killing them.

For the entire article, please click on the link below:

https://www.medicalnewstoday.com/articles/stem-cell-therapy-for-non-small-cell-lung-cancer#can-it-treat-nsclc

Advances of Exosome-Based Therapeutics in the Clinic

Organicell Regenerative Medicine: Advances of Exosome-Based Therapeutics in the Clinic

Author: Greta Gohring (Research Assistant, Organicell Regenerative Medicine)

Regenerative Medicine is a rapidly expanding sector of biotechnology with numerous innovative therapeutics. Regenerative medicine encompasses a multitude of specialties such as orthopedics, immunology, and cardiology, while following common trends within the fields of tissue and cell engineering. In contrast to common symptom-targeting therapeutics, which temporarily relieve and subdue conditions, regenerative medicine is designed to reprogram damaged or diseased tissues back to a healthy state. Through reprogramming, regenerative medicine has the potential to provide long-term effects in chronic and reoccurring symptomatic diseases.

Stem cell and other cell-based therapies have proven to be strong therapeutic candidates for many regenerative and tissue restorative applications.  However, complications with post transplantation viability, clinical reproducibility, and large-scale development have stalled these products in the path to drug approval.

In an effort to enhance and build from the lessons learned in cell-based research and clinical trials, researchers have begun to shift focus to cell-to-cell secreted factors such as extracellular vesicles. Extracellular vesicles, secreted from the cell membrane or the cell’s internal recycling pathways, carry many of the same molecular messengers and factors found to be therapeutic in cell therapies.

Therefore, through the development of technologies to isolate extracellular vesicles from sources such as cell cultures and biologic fluids, extracellular vesicle-based therapies have begun to take center stage in regenerative medicine clinical applications.

Therapeutic Potential of Exosomes

Exosomes are a subtype of extracellular vesicles derived from the cell’s recycling pathway, specifically the endosome. During exosome formation, small nucleic acids, enzymes, and other molecular mediators are packaged into lipid membranes and secreted out of the cells. These exosomes are then absorbed by surrounding cells as a form of cell-to-cell communication.

The absorption of exosomes into various cell types can lead to modifications in gene expression, cell metabolism, and other signaling pathways. Depending on the cell of origin, exosomes have been linked to regenerative effects via the suppression of pro-inflammatory response and immune activation, as well as the promotion of cell proliferation and enhancement of tissue wound healing.

For the entire article, please click on the link below:

Organicell Regenerative Medicine: Advances of Exosome-Based Therapeutics in the Clinic | BioInformant

 

Designer neurons offer new hope for treatment of Parkinson’s disease

 

 

Neurodegenerative diseases damage and destroy neurons, ravaging both mental and physical health. Parkinson’s disease, which affects over 10 million people worldwide, is no exception. The most obvious symptoms of Parkinson’s disease arise after the illness damages a specific class of neuron located in the midbrain. The effect is to rob the brain of dopamine — a key neurotransmitter produced by the affected neurons.

In new research, Jeffrey Kordower and his colleagues describe a process for converting non-neuronal cells into functioning neurons able to take up residence in the brain, send out their fibrous branches across neural tissue, form synapses, dispense dopamine and restore capacities undermined by Parkinson’s destruction of dopaminergic cells.

The current proof-of-concept study reveals that one group of experimentally engineered cells performs optimally in terms of survival, growth, neural connectivity, and dopamine production, when implanted in the brains of rats. The study demonstrates that the result of such neural grafts is to effectively reverse motor symptoms due to Parkinson’s disease.

Stem cell replacement therapy represents a radical new strategy for the treatment of Parkinson’s and other neurodegenerative diseases. The futuristic approach will soon be put to the test in the first of its kind clinical trial, in a specific population of Parkinson’s disease sufferers, bearing a mutation in the gene parkin. The trial will be conducted at various locations, including the Barrow Neurological Institute in Phoenix, with Kordower as principal investigator.

The work is supported through a grant from the Michael J. Fox Foundation.

“We cannot be more excited by the opportunity to help individuals who suffer from this genetic form of Parkinson’s disease, but the lessons learned from this trial will also directly impact patients who suffer from sporadic, or non-genetic forms of this disease,” Kordower says.

Kordower directs the ASU-Banner Neurodegenerative Disease Research Center at Arizona State University and is the Charlene and J. Orin Edson Distinguished Director at the Biodesign Institute. The new study describes in detail the experimental preparation of stem cells suitable for implantation to reverse the effects of Parkinson’s disease.

The research appears in the current issue of the npj journal Nature Regenerative Medicine.

New perspectives on Parkinson’s disease

You don’t have to be a neuroscientist to identify a neuron. Such cells, with their branching arbor of axons and dendrites are instantly recognizable and look like no other cell type in the body. Through their electrical impulses, they exert meticulous control over everything from heart rate to speech. Neurons are also the repository of our hopes and anxieties, the source of our individual identity.

For the entire article / study, please click on the link below:

https://www.sciencedaily.com/releases/2022/05/220511123615.htm

 

 

What are the advantages of using Stem Cell Therapy Vs. Surgery?

If you’ve suffered from a ligament or joint damage like an ACL tear, MCL tear, meniscus tear, or rotator cuff tear, or if you need knee replacement or shoulder, hip, neck, back, elbow, or any other orthopedic surgeries, we believe that stem cell treatment is a better option than surgery.

Here’s why:

  • After stem cell treatment, your body repairs and heals itself. You will generate new cartilage and ligaments, giving you the same feel and function you had before the injury.
  • You’ll enjoy a faster healing time. Your body only needs to heal the original injury, not the trauma of surgery in addition to the injury.
  • Your own original, actual tissue is much better for your body than anything surgery can create.
  • You won’t have to take powerful, risky medications to manage your pain as you heal. The more powerful the medicine, the more powerful the side effects – so it’s good to avoid them if you can.
  • Best of all, we are using your own body to heal you. There are no side effects.

To learn more, please contact Miami Stem Cell (305) 598-7777 or visit us at: www.stemcellmia.com

New Non-Invasive Back Pain Treatments Using Stem Cell Therapy!

Causes of Back Pain Addressed with Bone Marrow Stem Cell Therapy at Miami Stem Cell:
 
*Degenerative disc disease
*Bulging Discs
*Spinal Stenosis
*Sprains or strains to muscles or ligaments
*Herniated discs
*Inflammation in the sacroiliac joint
*Pinched nerves
*Arthritis
*Osteoarthritis
*Injury from a fall or accident
*Nerve compression
*Facet Arthritis
*Slipped Disc
 
To learn more, please visit Miami Stem Cell www.stemcellmia.com or call us (305) 598-7777 to schedule a free evaluation today! 

Stem cell therapy for Alzheimer’s disease

 

Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by memory loss and cognitive impairment. It is caused by synaptic failure and excessive accumulation of misfolded proteins. To date, almost all advanced clinical trials on specific AD-related pathways have failed mostly due to a large number of neurons lost in the brain of patients with AD. Also, currently available drug candidates intervene too late. Stem cells have improved characteristics of self-renewal, proliferation, differentiation, and recombination with the advent of stem cell technology and the transformation of these cells into different types of central nervous system neurons and glial cells. Stem cell treatment has been successful in AD animal models. Recent preclinical studies on stem cell therapy for AD have proved to be promising. Cell replacement therapies, such as human embryonic stem cells or induced pluripotent stem cell–derived neural cells, have the potential to treat patients with AD, and human clinical trials are ongoing in this regard. However, many steps still need to be taken before stem cell therapy becomes a clinically feasible treatment for human AD and related diseases. This paper reviews the pathophysiology of AD and the application prospects of related stem cells based on cell type.

Alzheimer’s disease (AD), a progressive neurodegenerative disorder featuring memory loss and cognitive impairment, is caused by synaptic failure and the excessive accumulation of misfolded proteins. Stem cell-based therapies cast a new hope for AD treatment as a replacement or regeneration strategy. The results from recent preclinical studies regarding stem cell-based therapies are promising. Human clinical trials are now underway. However, a number of questions remain to be answered prior to safe and effective clinical translation. This review explores the pathophysiology of AD and summarizes the relevant stem cell research according to cell type. We also briefly summarize related clinical trials. Finally, future perspectives are discussed with regard to their clinical applications.

INTRODUCTION

Dementia is a neurodegenerative, debilitating, and fatal disease characterized by progressive cognitive impairment, behavioral disorders, and loss of function in daily life. Alzheimer’s disease (AD) is the most common cause of dementia, accounting for 50%-70% of dementia cases worldwide[]. The 2018 World Alzheimer’s Disease Report shows that 50 million people worldwide have dementia. With a new case occurring every 3 s worldwide, AD has rapidly become an epidemic, with the number of cases predicted to be 152 million by 2050[].

AD has several neuropathological hallmarks, including the deposition of β-amyloid (Aβ) peptides in the extracellular matrix between neurons (known as amyloid plaques), the intracellular formation of neurofibrillary tangles arising from the accumulation of hyperphosphorylated tau protein in neurons, neuronal loss, neuroinflammation, and oxidative stress. Despite advances in understanding the etiology of AD, treating the disease by retaining acetylcholine and reducing glutamate is limited to symptom management[]. Although cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers combined with some relatively new clinical standards can help diagnose alive patients, the certainty of diagnosis was achieved only by post-mortem autopsy[]. These criteria highlight that the gold standard for the etiological diagnosis remains the neuropathological assessment. Accordingly, the results of CSF biomarkers for AD may provide explanatory evidence for neurocognitive symptoms and predict the type of evolution, especially when there are no other obvious causes of cognitive impairment. Reducing Aβ levels has been the dominant treatment strategy in development to halt, retard, or even reverse the progression of AD pathology. In fact, currently available treatments include three types of cholinesterase inhibitors, one N-methyl-daspartate receptor antagonist, and one combined drug therapy (memantine plus donepezil) are currently approved for clinical use[]. However, it is unclear how valuable such a palliative drug-based approach can be.

Therefore, new and effective treatments, such as removing toxic deposits and replacing lost neurons, need to be developed to improve the pathological state of the disease, stimulate neural precursors, prevent nerve death, enhance structural neural plasticity, and so forth. At the same time, it is also necessary to provide a better environment for the remaining cells. Current breakthroughs in preclinical research and clinical trials of stem cells have ignited hope for the treatment of refractory neurodegenerative diseases such as AD. They are considered to be the most suitable choice to provide uniform and unique cells required for cell replacement therapy[]. This review focuses on the mechanisms of AD pathogenesis and discusses clinical and preclinical findings on the role of stem cells in the treatment of AD.

For the entire article, please click on the link below:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477654/